BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 23651359)

  • 1. Synthesis, pharmacological characterization, and docking analysis of a novel family of diarylisoxazoles as highly selective cyclooxygenase-1 (COX-1) inhibitors.
    Vitale P; Tacconelli S; Perrone MG; Malerba P; Simone L; Scilimati A; Lavecchia A; Dovizio M; Marcantoni E; Bruno A; Patrignani P
    J Med Chem; 2013 Jun; 56(11):4277-99. PubMed ID: 23651359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diarylheterocycle core ring features effect in selective COX-1 inhibition.
    Perrone MG; Vitale P; Malerba P; Altomare A; Rizzi R; Lavecchia A; Di Giovanni C; Novellino E; Scilimati A
    ChemMedChem; 2012 Apr; 7(4):629-41. PubMed ID: 22278975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural basis for selective inhibition of Cyclooxygenase-1 (COX-1) by diarylisoxazoles mofezolac and 3-(5-chlorofuran-2-yl)-5-methyl-4-phenylisoxazole (P6).
    Cingolani G; Panella A; Perrone MG; Vitale P; Di Mauro G; Fortuna CG; Armen RS; Ferorelli S; Smith WL; Scilimati A
    Eur J Med Chem; 2017 Sep; 138():661-668. PubMed ID: 28710965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective COX-1 inhibition as a target of theranostic novel diarylisoxazoles.
    Vitale P; Perrone MG; Malerba P; Lavecchia A; Scilimati A
    Eur J Med Chem; 2014 Mar; 74():606-18. PubMed ID: 24531199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hydroxychavicol, a novel betel leaf component, inhibits platelet aggregation by suppression of cyclooxygenase, thromboxane production and calcium mobilization.
    Chang MC; Uang BJ; Tsai CY; Wu HL; Lin BR; Lee CS; Chen YJ; Chang CH; Tsai YL; Kao CJ; Jeng JH
    Br J Pharmacol; 2007 Sep; 152(1):73-82. PubMed ID: 17641677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor.
    Riendeau D; Percival MD; Boyce S; Brideau C; Charleson S; Cromlish W; Ethier D; Evans J; Falgueyret JP; Ford-Hutchinson AW; Gordon R; Greig G; Gresser M; Guay J; Kargman S; Léger S; Mancini JA; O'Neill G; Ouellet M; Rodger IW; Thérien M; Wang Z; Webb JK; Wong E; Chan CC
    Br J Pharmacol; 1997 May; 121(1):105-17. PubMed ID: 9146894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isoxazole-Based-Scaffold Inhibitors Targeting Cyclooxygenases (COXs).
    Perrone MG; Vitale P; Panella A; Ferorelli S; Contino M; Lavecchia A; Scilimati A
    ChemMedChem; 2016 Jun; 11(11):1172-87. PubMed ID: 27136372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel synthesis of 3,4-diarylisoxazole analogues of valdecoxib: reversal cyclooxygenase-2 selectivity by sulfonamide group removal.
    Di Nunno L; Vitale P; Scilimati A; Tacconelli S; Patrignani P
    J Med Chem; 2004 Sep; 47(20):4881-90. PubMed ID: 15369392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nitrooxymethyl-substituted analogues of rofecoxib: synthesis and pharmacological characterization.
    Boschi D; Cena C; Di Stilo A; Rolando B; Manzini P; Fruttero R; Gasco A
    Chem Biodivers; 2010 May; 7(5):1173-82. PubMed ID: 20491074
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiplatelet effect of phloroglucinol is related to inhibition of cyclooxygenase, reactive oxygen species, ERK/p38 signaling and thromboxane A2 production.
    Chang MC; Chang HH; Chan CP; Chou HY; Chang BE; Yeung SY; Wang TM; Jeng JH
    Toxicol Appl Pharmacol; 2012 Sep; 263(3):287-95. PubMed ID: 22789837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trimethyl-4-oxo-4,5,6,7-tetrahydroindazole-1-acetic acid: a new lead compound with selective COX-2 inhibitory activity.
    Abdel-Rahman HM; Ozadali K
    Arch Pharm (Weinheim); 2012 Nov; 345(11):878-83. PubMed ID: 22907715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ASP6537, a novel highly selective cyclooxygenase-1 inhibitor, exerts potent antithrombotic effect without "aspirin dilemma".
    Sakata C; Kawasaki T; Kato Y; Abe M; Suzuki K; Ohmiya M; Funatsu T; Morita Y; Okada M
    Thromb Res; 2013 Jul; 132(1):56-62. PubMed ID: 23522855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, Synthesis and Biological Evaluation of New 1,3-diphenyl-3- (phenylamino)propan-1-ones as Selective Cyclooxygenase (COX-2) Inhibitors.
    Farzaneh S; Shahhosseini S; Arefi H; Daraei B; Esfahanizadeh M; Zarghi A
    Med Chem; 2018; 14(7):652-659. PubMed ID: 29804536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel thienylacylhydrazone derivatives inhibit platelet aggregation through cyclic nucleotides modulation and thromboxane A2 synthesis inhibition.
    Brito FC; Kummerle AE; Lugnier C; Fraga CA; Barreiro EJ; Miranda AL
    Eur J Pharmacol; 2010 Jul; 638(1-3):5-12. PubMed ID: 20412790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical pharmacology of cyclooxygenase inhibition and pharmacodynamic interaction with aspirin by floctafenine in Thai healthy subjects.
    Maenthaisong R; Tacconelli S; Sritara P; Del Boccio P; Di Francesco L; Sacchetta P; Archararit N; Aryurachai K; Patrignani P; Suthisisang C
    Int J Immunopathol Pharmacol; 2013; 26(2):403-17. PubMed ID: 23755755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclooxygenase-1 and cyclooxygenase-2 inhibition of novel 1,2-disubstituted imidazoles.
    Handler N; Jaeger W; Kuen-Krismer B; Erker T
    Arch Pharm (Weinheim); 2005 Dec; 338(12):602-4. PubMed ID: 16353278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of prostacyclin in the cardiovascular response to thromboxane A2.
    Cheng Y; Austin SC; Rocca B; Koller BH; Coffman TM; Grosser T; Lawson JA; FitzGerald GA
    Science; 2002 Apr; 296(5567):539-41. PubMed ID: 11964481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human pharmacology of naproxen sodium.
    Capone ML; Tacconelli S; Sciulli MG; Anzellotti P; Di Francesco L; Merciaro G; Di Gregorio P; Patrignani P
    J Pharmacol Exp Ther; 2007 Aug; 322(2):453-60. PubMed ID: 17473175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis, and biological evaluation of ketoprofen analogs as potent cyclooxygenase-2 inhibitors.
    Zarghi A; Ghodsi R
    Bioorg Med Chem; 2010 Aug; 18(16):5855-60. PubMed ID: 20650641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclooxygenase-2 inhibitors. 1,5-diarylpyrrol-3-acetic esters with enhanced inhibitory activity toward cyclooxygenase-2 and improved cyclooxygenase-2/cyclooxygenase-1 selectivity.
    Biava M; Porretta GC; Poce G; Supino S; Forli S; Rovini M; Cappelli A; Manetti F; Botta M; Sautebin L; Rossi A; Pergola C; Ghelardini C; Vivoli E; Makovec F; Anzellotti P; Patrignani P; Anzini M
    J Med Chem; 2007 Nov; 50(22):5403-11. PubMed ID: 17915854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.